Table 1.
Differential abundance analysis results at the lipid category level.
| Category | Total | More Abundant Features | Less Abundant Features | ||||
|---|---|---|---|---|---|---|---|
| Expected | Observed | p-Adjust | Expected | Observed | p-Adjust | ||
| Fatty Acyls [FA] | 12 | 2.989 | 2 | 1 | 3.947 | 0 | 1 |
| Glycerophospholipids [GP] | 205 | 51.055 | 37 | 1 | 67.424 | 88 | 0.00503 |
| Prenol Lipids [PR] | 5 | 1.245 | 0 | 1 | 1.644 | 0 | 1 |
| Sphingolipids [SP] | 281 | 69.983 | 79 | 0.09861 | 92.420 | 81 | 1 |
| Sphingolipids [SP]–Low m/z | 33 | 8.219 | 3 | 1 | 10.854 | 16 | 0.141 |
| Sphingolipids [SP]–High m/z | 248 | 61.764 | 76 | 0.00967 | 81.567 | 65 | 1 |
| Sterol Lipids [ST] | 23 | 5.728 | 13 | 0.00643 | 7.084 | 3 | 1 |
For each category of lipids, the number of observed more and less abundant features was recorded and compared to the number of expected more and less abundant features to statistically evaluate the differential abundance of that specific lipid category. The p-values were calculated using a hypergeometric test and adjusted for multiple testing using the Benjamini–Hochberg technique [56]. This revealed two statistically significant, more abundant lipid categories and one statistically significant, less abundant lipid category in cancer compared to non-cancer, which are bolded.